GW’s extensive research into the pharmacology of cannabinoids continues to yield highly promising data and new intellectual property across a range of therapeutic areas. GW continues to invest in research to accelerate further growth and value creation through the development of medicines that address serious unmet medical needs.
Epidiolex® is an investigational product outside of the United States. Sativex® is not approved in the United States for any indication; it is approved for MS Spasticity in certain countries outside of the United States. All other products mentioned are investigational only. See www.gwpharm.com for full details.